University of Pittsburgh receives $8 million to study alcohol and HIV interactions

December 17, 2001

PITTSBURGH, Dec. 17 - Alcohol is the most common drug of abuse among people infected with HIV. To study how alcohol use and abuse interacts with HIV infection and treatment, the University of Pittsburgh and the Pittsburgh Veterans Administration Medical Center have received an $8 million grant from the National Institute on Alcohol Abuse and Alcoholism.

"We know that alcohol and unprotected sex are common bedfellows. Alcohol use and abuse may be an important risk factor for HIV infection," said the study's principal investigator, Amy Justice, M.D., Ph.D., of the University of Pittsburgh and the Pittsburgh VA. "Overuse of alcohol likely aggravates common related medical and psychiatric diseases such as hepatitis C and depression. Alcohol use may also decrease the benefit of HIV treatment by causing people to miss taking their medication and increasing the risk of treatment toxicity."

An expansion of the ongoing Veterans Aging Cohort Study (VACS), the current study -- VACS 5 -- will identify the role of alcohol use and abuse in determining health and quality of life among aging veterans with and without HIV. VACS 5 also will examine the effect alcohol has on susceptibility to drug toxicity and the progression of related diseases.

The need for this study is discussed in a special supplement to the recently released December issue of the Journal of Clinical Epidemiology.

By involving veterans who are HIV-negative as the control group, the study will help to identify alcohol-related effects that are specific to aging people with HIV, and those that affect the aging regardless of their HIV status. The study's results will help physicians understand what level of alcohol consumption may be dangerous and will help them tailor treatment for all people who use alcohol.

Dr. Justice and co-principal investigator Joseph Conigliaro, M.D., M.P.H., also of the University of Pittsburgh and the Pittsburgh VA, will lead the study of 2,000 HIV-infected veterans and 2,000 non-HIV-infected, matched controls from VA facilities in Manhattan/Brooklyn, Bronx, Atlanta, Los Angeles and Houston. At these five clinical sites, researchers will examine the impact of alcohol use and abuse on related diseases, drug toxicity, death, quality of life, treatment success, use of health care services and prescription drug use and adherence.

The VA's national electronic medical records system, which includes laboratory and pharmacy data and can track patient status over time, offers unique advantages for such a long-term study.

"Because the VA pays for all currently approved antiretroviral medications and can track patients among several clinical sites, we expect to achieve excellent follow-up on these patients," says Dr. Conigliaro. "In addition, patients with HIV infection in the VA system are predominantly members of important and understudied minority groups."
The national VA hospital system is the largest single provider of HIV services in the United States, and in 2000 it treated some 18,000 HIV-infected veterans. The VA has a patient population that includes minorities, economically disadvantaged persons and IV drug users in numbers disproportionate to their prevalence in the general population. An earlier study, VACS 3, found that 40 percent of HIV-infected VA patients reported current drinking, 35 percent reported binge drinking and 21 percent had Alcohol Use Disorders Identification Test scores consistent with hazardous drinking.

At the University of Pittsburgh, Dr. Justice is a Robert Wood Johnson Generalist Faculty Scholar and associate professor in the School of Medicine, and associate professor of health services research at the Graduate School of Public Health. Dr. Conigliaro is associate professor in the School of Medicine. Both are staff physicians at the Pittsburgh VA Medical Center.

University of Pittsburgh Medical Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to